1.DRGs-based analysis of the service capacity changes of county-level hospitals in Wenzhou
Xiangyang ZHANG ; Jincai WEI ; Jinguo CHENG ; Yunzeng ZHENG ; Yihua XU ; Ying WANG ; Chun CHEN
Chinese Journal of Hospital Administration 2017;33(2):110-112
Objective To analyze and compare the capacity and efficiency of county-level hospitals′medical service by using the diagnosis related groups ( DRGs ) method. Methods The homepage data of discharged inpatients from seven county-level hospitals in Wenzhou region in 2013 - 2015 period were analyzed, for measurement of the medical service capacity changes of such hospitals using the number of DRGs, total multiplicity of weight, and CMI value, and that of their medical service efficiency changes using expense consumption index and time consumption index. Results The study found in the seven hospitals 8. 49% increase of the total number of DRGs, 17. 34% increase of total multiplicity of weight, and 5. 06%increase of CMI value, with unchanged expense consumption index and 9. 82% decrease of the time consumption index. These facts evidenced enhancements of these hospitals in both service capacity and service efficiency in general. Conclusions DRGs as tools prove useful objectively and scientifically. Policies of Two emphases at primary ends and two enhancements have been implemented desirably.
2. Research progress of β2 microglobulin
Xiaoyi ZHANG ; Zheng KUAI ; Yunzeng ZOU
Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(4):390-396
β2 microglobulin (β2-MG) is a key component I molecule of the major histocompatibility complex class that assists in the cytotoxic T lymphocyte (CTL) immune response. Serum β2-MG content is dynamically correlated with many diseases. Most studies on β2-MG mainly focus on the pathogenesis of kidney disease, tumor and amyloid fibrils. In recent years, some studies have found that β2-MG is also involved in the adverse prognosis of cardiovascular system, cognitive impairment of aging and antibacterial effects. This paper summarized the domestic and foreign studies on β2-MG in recent years, and proposed the possible role of β2-MG in multi-system human body and its potential application prospect of drug molecular targeting.
3. Angiotensin receptor neprilysin inhibitor in elderly with hypertension
Zheng KUAI ; Xiaoyi ZHANG ; Yunzeng ZOU
Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(4):442-445
Angiotensin receptor/neprilysin inhibitor (ARNI) is a novel combination drug that is a dual inhibitor of angiotensin receptor and neprilysin. In June 2021, the National Medical Products Administration approved ARNI for hypertension indications. This review provides an update of current literature on ARNI in elderly hypertension.